Literature DB >> 15085188

Undermining the endothelium by ablation of MAPK-MEF2 signaling.

Eric N Olson1.   

Abstract

Numerous stimuli activate Big MAPK-1 (BMK1), an MAPK that activates the myocyte enhancer factor-2 (MEF2) transcription factor. Conditional gene deletion showed BMK1 to be required for survival of endothelial cells. An active form of MEF2C could partially bypass the requirement for BMK1 for endothelial cell survival in vitro. These findings reveal an essential role for BMK1-MEF2 signaling in an endothelial cell survival pathway and raise interesting questions about the molecular basis of this response.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15085188      PMCID: PMC385412          DOI: 10.1172/JCI21497

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  20 in total

1.  Mekk3 is essential for early embryonic cardiovascular development.

Authors:  J Yang; M Boerm; M McCarty; C Bucana; I J Fidler; Y Zhuang; B Su
Journal:  Nat Genet       Date:  2000-03       Impact factor: 38.330

2.  The transcription factor MEF2C-null mouse exhibits complex vascular malformations and reduced cardiac expression of angiopoietin 1 and VEGF.

Authors:  W Bi; C J Drake; J J Schwarz
Journal:  Dev Biol       Date:  1999-07-15       Impact factor: 3.582

3.  Neuronal activity-dependent cell survival mediated by transcription factor MEF2.

Authors:  Z Mao; A Bonni; F Xia; M Nadal-Vicens; M E Greenberg
Journal:  Science       Date:  1999-10-22       Impact factor: 47.728

4.  Control of mouse cardiac morphogenesis and myogenesis by transcription factor MEF2C.

Authors:  Q Lin; J Schwarz; C Bucana; E N Olson
Journal:  Science       Date:  1997-05-30       Impact factor: 47.728

5.  A network of mitogen-activated protein kinases links G protein-coupled receptors to the c-jun promoter: a role for c-Jun NH2-terminal kinase, p38s, and extracellular signal-regulated kinase 5.

Authors:  M J Marinissen; M Chiariello; M Pallante; J S Gutkind
Journal:  Mol Cell Biol       Date:  1999-06       Impact factor: 4.272

6.  Big mitogen-activated kinase regulates multiple members of the MEF2 protein family.

Authors:  Y Kato; M Zhao; A Morikawa; T Sugiyama; D Chakravortty; N Koide; T Yoshida; R I Tapping; Y Yang; T Yokochi; J D Lee
Journal:  J Biol Chem       Date:  2000-06-16       Impact factor: 5.157

7.  Targeted deletion of BMK1/ERK5 in adult mice perturbs vascular integrity and leads to endothelial failure.

Authors:  Masaaki Hayashi; Sung-Woo Kim; Kyoko Imanaka-Yoshida; Toshimichi Yoshida; E Dale Abel; Brian Eliceiri; Young Yang; Richard J Ulevitch; Jiing-Dwan Lee
Journal:  J Clin Invest       Date:  2004-04       Impact factor: 14.808

8.  Big mitogen-activated protein kinase (BMK1)/ERK5 protects endothelial cells from apoptosis.

Authors:  Xinchun Pi; Chen Yan; Bradford C Berk
Journal:  Circ Res       Date:  2003-12-11       Impact factor: 17.367

9.  Interaction of myocyte enhancer factor 2 (MEF2) with a mitogen-activated protein kinase, ERK5/BMK1.

Authors:  C C Yang; O I Ornatsky; J C McDermott; T F Cruz; C A Prody
Journal:  Nucleic Acids Res       Date:  1998-10-15       Impact factor: 16.971

10.  Requirement of the MADS-box transcription factor MEF2C for vascular development.

Authors:  Q Lin; J Lu; H Yanagisawa; R Webb; G E Lyons; J A Richardson; E N Olson
Journal:  Development       Date:  1998-11       Impact factor: 6.868

View more
  13 in total

Review 1.  Targeting multidrug-resistant tuberculosis (MDR-TB) by therapeutic vaccines.

Authors:  Satria A Prabowo; Matthias I Gröschel; Ed D L Schmidt; Alena Skrahina; Traian Mihaescu; Serap Hastürk; Rotislav Mitrofanov; Edita Pimkina; Ildikó Visontai; Bouke de Jong; John L Stanford; Père-Joan Cardona; Stefan H E Kaufmann; Tjip S van der Werf
Journal:  Med Microbiol Immunol       Date:  2012-11-10       Impact factor: 3.402

2.  Expression of myocyte enhancer factor-2 and downstream genes in ground squirrel skeletal muscle during hibernation.

Authors:  Shannon N Tessier; Kenneth B Storey
Journal:  Mol Cell Biochem       Date:  2010-07-09       Impact factor: 3.396

3.  Tumor necrosis factor alpha-mediated reduction of KLF2 is due to inhibition of MEF2 by NF-kappaB and histone deacetylases.

Authors:  Ajay Kumar; Zhiyong Lin; Sucharita SenBanerjee; Mukesh K Jain
Journal:  Mol Cell Biol       Date:  2005-07       Impact factor: 4.272

4.  Control of endothelial cell proliferation and migration by VEGF signaling to histone deacetylase 7.

Authors:  Shusheng Wang; Xiumin Li; Maribel Parra; Eric Verdin; Rhonda Bassel-Duby; Eric N Olson
Journal:  Proc Natl Acad Sci U S A       Date:  2008-05-28       Impact factor: 11.205

5.  Myocyte enhancer factor 2D promotes tumorigenicity in malignant glioma cells.

Authors:  Youguang Zhao; Ying Li; Yuan Ma; Songtao Wang; Jingmin Cheng; Tao Yang; Zhiyong Sun; Yongqin Kuang; Haidong Huang; Kexia Fan; Jianwen Gu
Journal:  Tumour Biol       Date:  2015-08-04

6.  Bone marrow-induced Mef2c deficiency delays B-cell development and alters the expression of key B-cell regulatory proteins.

Authors:  Irina Debnath; Kirstin M Roundy; Peter D Pioli; Janis J Weis; John H Weis
Journal:  Int Immunol       Date:  2012-10-19       Impact factor: 4.823

7.  Computational identification of transcriptional regulators in human endotoxemia.

Authors:  Tung T Nguyen; Panagiota T Foteinou; Steven E Calvano; Stephen F Lowry; Ioannis P Androulakis
Journal:  PLoS One       Date:  2011-05-27       Impact factor: 3.240

Review 8.  The case for inhibiting p38 mitogen-activated protein kinase in heart failure.

Authors:  Pelin Arabacilar; Michael Marber
Journal:  Front Pharmacol       Date:  2015-05-12       Impact factor: 5.810

Review 9.  ERK5 Mediated Signalling in Diabetic Retinopathy.

Authors:  Yuexiu Wu; Subrata Chakrabarti
Journal:  Med Hypothesis Discov Innov Ophthalmol       Date:  2015

Review 10.  Cellular signaling and potential new treatment targets in diabetic retinopathy.

Authors:  Zia A Khan; Subrata Chakrabarti
Journal:  Exp Diabetes Res       Date:  2007
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.